Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: d emden m, sullivan d. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators. Simes RJ, et al. Among authors: sullivan d. Circulation. 2002 Mar 12;105(10):1162-9. doi: 10.1161/hc1002.105136. Circulation. 2002. PMID: 11889008
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
Stocker R, Pollicino C, Gay CA, Nestel P, Colquhoun D, Whiting M, Tonkin A, Sullivan D, Simes J. Stocker R, et al. Among authors: sullivan d. Atherosclerosis. 2006 Jul;187(1):198-204. doi: 10.1016/j.atherosclerosis.2005.09.004. Epub 2005 Oct 10. Atherosclerosis. 2006. PMID: 16219312
National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.
Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K, Sullivan D, Thompson P, Vale M, Cooper C, Robinson M, Clune E; National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Tonkin A, et al. Among authors: sullivan d. Heart Lung Circ. 2005 Dec;14(4):275-91. doi: 10.1016/j.hlc.2005.10.010. Heart Lung Circ. 2005. PMID: 16361000 No abstract available.
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamäki H, Keech A; FIELD Study Investigators. Sullivan D, et al. Diabetes Res Clin Pract. 2011 Nov;94(2):284-90. doi: 10.1016/j.diabres.2011.07.028. Epub 2011 Aug 21. Diabetes Res Clin Pract. 2011. PMID: 21862166 Clinical Trial.
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S; LIPID Study Investigators. White HD, et al. Among authors: sullivan d. J Am Coll Cardiol. 2014 Feb 4;63(4):345-54. doi: 10.1016/j.jacc.2013.08.1643. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24140630 Free article. Clinical Trial.
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Cho L, et al. Among authors: sullivan d. Clin Cardiol. 2014 Mar;37(3):131-9. doi: 10.1002/clc.22248. Epub 2014 Jan 29. Clin Cardiol. 2014. PMID: 24477778 Free PMC article. Clinical Trial.
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A, Mann K, Colquhoun D, Zeller T, Hunt D, Simes J, Sullivan D, Sydow K, West M, White H, Blankenberg S, Tonkin AM; LIPID Study Investigators. Funke-Kaiser A, et al. Among authors: sullivan d. Int J Cardiol. 2014 Mar 15;172(2):411-8. doi: 10.1016/j.ijcard.2014.01.064. Epub 2014 Jan 24. Int J Cardiol. 2014. PMID: 24508492 Clinical Trial.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. Raal FJ, et al. Among authors: sullivan d. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1. Lancet. 2015. PMID: 25282519 Clinical Trial.
2,528 results